[Is pathogenetically-founded therapy of chronic inflammatory bowel disease in sight?].
Miller
B
B
Medizinische Klinik III, St.-Johannes-Hospital Duisburg-Hamborn.
D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000503:physiopathology; D003424:Crohn Disease / Q000188:drug therapy* / Q000503:physiopathology; D005544:Forecasting; D006801:Humans; D007375:Interleukin-1 / Q000037:antagonists & inhibitors / Q000502:physiology; D007975:Leukotriene B4 / Q000037:antagonists & inhibitors / Q000502:physiology; D008084:Lipoxygenase / Q000502:physiology; D016859:Lipoxygenase Inhibitors / Q000627:therapeutic use; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors / Q000502:physiology
D007375:Interleukin-1; D016859:Lipoxygenase Inhibitors; D017472:Receptors, Interleukin-1; D007975:Leukotriene B4; D008084:Lipoxygenase
1st eine pathogenetisch begründete Therapie der chronisch-entzündlichen Darmerkrankungen in Sicht?